AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01668485 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hypoglycemic and euglycemic glucose clamp
Description: Each study participant will be subjected to a continuous infusion of insulin at a rate of 0.8 mU·kg-1·min-1 to induce hypoglycemia (blood glucose 2.8-3 mmol/l) for 30 minutes. At least two weeks later an identical insulin infusion will be administered and euglycemia (blood glucose 5 mmol/l) will be targeted. The order of these interventions will be subject to randomization.
Study NCT01668485 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Hypoglycemic and euglycemic glucose clamp
Description: Each study participant will be subjected to a continuous infusion of insulin at a rate of 0.8 mU·kg-1·min-1 to induce hypoglycemia (blood glucose 2.8-3 mmol/l) for 30 minutes. At least two weeks later an identical insulin infusion will be administered and euglycemia (blood glucose 5 mmol/l) will be targeted. The order of these interventions will be subject to randomization.
Study NCT03368027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A cognitive-behavioral intervention program
Description: In this program, participants receive a training of assertive skills, social skills, acceptance, among other psychological aspects.
Study NCT03368027 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard intervention
Description: Participants receive different activities conducted by a psychologist in the association where the attend.
Study NCT00421408 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein supplement
Description: 40-g whey protein supplement daily for 18 months
Study NCT00421408 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplement daily for 18 months
Study NCT00311831 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard gastroenteritis education
Description: Subjects in this arm of the study will receive an educational handout on gastroenteritis education.
Study NCT02783105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Musical intervention
Study NCT00311831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extensive gastroenteritis education
Description: Subjects in this arm of the study will receive an gastroenteritis educational handout as well a home visitation from a trained counselor.
Study NCT06549920 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Internal mammary node irradiation
Description: Irradiation of the internal mammary nodes in intercostal space 1-4.
Study NCT01724814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM12460A
Description: Single dose SC administration ranging from 1.2 nmol/kg to 19.2 nmol/kg of HM12460A
Study NCT02783105 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Patients wear headphones twice a day during 30 minutes, starting at the onset of desedation (Day 0) until day 21, but no music is provided (blank playlist): Sham
Study NCT03850444 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Study NCT03850444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Study NCT03850444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Study NCT03850444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Study NCT04859556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alcon 25Gauge, 10,000 cuts per minute Ultravit cutter
Description: a proprietary Vitrector from Alcon for the use on the Constellation system
Study NCT04859556 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alcon 25Gauge, 5,000 cuts per minute Ultravit cutter
Description: a proprietary Vitrector from Alcon for the use on the Constellation system
Study NCT01724814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Singe dose SC administration of Placebo
Study NCT03329833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivational interviewing will consist of weekly phone calls for two months, bi-weekly phone calls for two months, and monthly phone calls for two months.
Study NCT03329833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based application
Description: Web-based application participants will be asked to log activity at least on a daily basis.
Study NCT01955265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sports mentorship programme
Description: 1.5-hour sports mentorship session once a week, 18 weeks total.
Study NCT01955265 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health promotion
Description: The access to a health promotion website any time during the intervention period. The website contains general health information including those related to physical activity.
Study NCT02468505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEPS
Description: time-limited behavioral counseling, online materials, training
Study NCT03869710 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Dry-Needling Therapy
Description: The needle will be insert under ultrasound guidance to elicit the myofascial response on the neck of the patients
Study NCT03688295 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No antibiotics
Description: Patients will not receive antiobitherapy post surgery for CAA
Study NCT03688295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: Patients will receive antiobitherapy post surgery for CAA
Study NCT02065245 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)
Description: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion
Study NCT02065245 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered by peripheral intravenous infusion.
Study NCT02065245 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)
Description: Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion.
Study NCT00103701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 15- 240 mg, Once or twice daily, 0-3 years depending on response.
Study NCT02766478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genistein
Description: Genistein is a natural supplement that comes from soy. Genistein will be taken orally (30 mg twice daily) for 12 weeks.
Study NCT02766478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo pill will be taken orally for 12 weeks.
Study NCT04699448 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional intervention.
Description: Diets designed for body weight loss, based on different macronutrient content.
Study NCT03494699 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary prevention
Description: group cognitive training (every month) App-based Cognitive Training at Home (using smartphone application) physical activity/body weight/smoking \& alcohol cessation monitoring and feedback
Study NCT01095224 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd35 Env A
Description: 1 x 10\^10 particle units (PU) administered as 1 mL intramuscularly (IM) in deltoid
Study NCT01095224 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd5 Env A
Description: 1 x 10\^10 PU administered as 1 mL IM in deltoid
Study NCT01095224 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd5 Env B
Description: 1 x 10\^10 PU administered as 1 mL IM in deltoid
Study NCT02941146 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ZELTIQ System
Description: The CoolSculpting System will be used to perform the treatments with the CoolAdvantage family of applicators.
Study NCT05732948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: autologous T cells & cyclophosphamide
Description: This is a phase I dose escalation study to assess the safety and tolerability using increasing doses of PD-1(programmed death 1)silent PSMA(prostate-specific membrane antigen)/PSCA(prostate stem cell antigen)targeted CAR-T administered one day after pretreatment with cyclophosphamide.
Study NCT01972087 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone simulation training
Description: The intervention consists of four 20-minute telephone simulation training sessions over a 4 month period (one session each month). Each 20-minute training session will include 3 simulated 9-1-1 calls, performed by a standardized caller (trained actor) and feedback will be provided right away by a trained observer who takes notes during the simulation calls and discusses the teaching points after the session. In total, the 9-1-1 dispatchers will receive 12 different simulated calls.
Study NCT03766919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant of the INVICTA lead
Description: The implant or the attempt to implant an INVICTA lead
Study NCT01890967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3015014
Description: Administered SC
Study NCT01890967 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT01890967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Administered orally
Study NCT01785615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 80mg
Study NCT01785615 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 80mg
Study NCT04520061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Insurance Navigation Program
Description: The program will be delivered via videoconferencing by a navigator over a 2-month period and will consist of 4 sessions. The navigation intervention sessions will be as follows: Session 1- Learning About Survivorship Healthcare Needs; Session 2- Learning About Your Plan in Relation to Policy; Session 3- Navigating One's Own Plan and Overcoming Obstacles; Session 4- Managing Care Costs.
Study NCT03782662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole capsules
Study NCT03782662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: Verapamil tablets
Study NCT03782662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin capsules
Study NCT03782662 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Midazolam oromucosal solution
Study NCT01890967 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Statin
Description: Administered orally
Study NCT03782662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam oromucosal solution
Study NCT01890967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Administered orally
Study NCT01890967 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ezetimibe
Description: Administered orally
Study NCT03782662 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for RV521
Description: Placebo for RV521 capsules
Study NCT03782662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV521
Description: RV521 capsules
Study NCT03843125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.
Study NCT03843125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.
Study NCT04460443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir
Description: Sofosbuvir once daily
Study NCT04460443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir ledipsavir
Description: Sofosbuvir ledipsavir once daily
Study NCT04460443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Daklatasuvir tablets
Study NCT00375856 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DePuy P.F.C.® Sigma Rotating Platform Knee
Description: no details
Study NCT04737590 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bioactive glass
Description: Comparison of bioactive glass to allogenic bone in pediatric bone cysts
Study NCT01081574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine
Description: 10 mg/qd/ 7 days.Oral dispersible tablets
Study NCT04154163 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dried blood Spot (DBS)
Description: Dried Blood Spot filter paper and sponges
Study NCT04154163 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Venous blood sampling
Description: Venous blood
Study NCT01005979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide, Rituximab, and Cyclophosphamide
Description: COHORT 1: Cyclophosphamide 250 mg/m2 day 1, 2 and 3, Rituximab 500 mg/m2 i.v. day 1, Lenalidomide 2.5 mg/day starting day 8-28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~COHORT 2: Cyclophosphamide 250mg/m2 day 1, 2 and 3. Rituximab 500 mg.m2 i.v. daY Lenalidomide 5 mg/day starting day 8 -28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~COHORT 3: Cyclophosphamide 250mg/m2 day 1, 2 and 3, Rituximab 500 mg.m2 i.v. day 1, Lenalidomide 10 mg/day starting day 8 -28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~COHORT 4: Cyclophosphamide 250mg/m2 day 1, 2 and 3, Rituximab 500 mg.m2 i.v. day 1, Lenalidomide 15 mg/day starting day 8 -28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~Patients will receive a total of 6-8 cycles.
Study NCT00054717 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tipranavir
Study NCT04391751 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carpal tunnel release and basal joint arthroplasty through single incision
Description: Group I: experimental - single incision The surgical technique chosen for thumb basal join was trapeziectomy with ligamentous reconstruction and tendon interposition (LRTI), using flexor carpi radialis (FCR). Through a dorsal approach over trapeziometacarpal joint, the entire trapezium was excised. Volar traction of FCR allowed us to longitudinally incise the deep leaflet of FCR tendon until flexor pollicis longus (FPL) tendon was clearly visualized. Then, ulnar half of FCR tendon was harvested proximally through a second transverse incision in middle third of the forearm and split all the way to its insertion on the index metacarpal. A hole was placed in the base of the first metacarpal and FCR tendon was routed through the bone canal and then fixed with non-reabsorbable sutures. Finally, the tendon remanent was rolled up and placed into the trapezial void to act as a spacer.
Study NCT04391751 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carpal tunnel release and basal joint arthroplasty through double incision
Description: Group II: active comparator - double incision Trapezial excision and ligament reconstruction were performed in the same way as in group I, except that FCR deep leaflet was not incised. After radial incision wound closure, carpal tunnel release was performed through a second separate longitudinal palmar incision.
Study NCT00054717 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ritonavir(r)
Study NCT00054717 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Comparator Protease Inhibitor (CPI)
Study NCT00958425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel
Description: Hyaluronic acid gel (20 mg/mL), 0.9 mL, intradermal over 2 cm area, once
Study NCT00958425 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Normal saline, 0.9 mL, intradermal over 2 cm area, once
Study NCT03390686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 15 mg/kg IV every 3 weeks on Day 1
Study NCT03390686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HD204
Description: 15 mg/kg IV every 3 weeks on Day 1
Study NCT03390686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles
Study NCT03390686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles
Study NCT03390686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
Study NCT03390686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
Study NCT01616563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Nutrition assessment, review of the basic principles of dietary intervention for metabolic syndrome with an emphasis on the clinical risk factors identified for each individual, joint goal setting to determine what dietary changes are feasible, considering intention and barriers to dietary behaviour change.
Study NCT01616563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Prescription and Fitness Program
Description: Exercise tests (aerobic fitness, muscular and flexibility tests) recommended by the Canadian Society of Exercise Physiology (CSEP), followed by an individualized exercise plan including fitness assessments.
Study NCT02424344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium/Formoterol
Description: Aclidinium bromide/Formoterol fumarate FDC 400/12μg dry powder for oral inhalation twice daily via Genuair inhaler
Study NCT02424344 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose-matched placebo dry powder for oral inhalation twice daily via Genuair inhaler
Study NCT03115775 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Conjugated linoleic acid
Description: Intervention will last up to 8 weeks. Subjects will receive conjugated linoleic acid (4000 mg Tonalin FFA 80) daily.
Study NCT03115775 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Intervention will last up to 8 weeks. Subjects will receive vitamin D3 (2000 IU) daily.
Study NCT03115775 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Conjugated linoleic acid and Vitamin D
Description: Intervention will last up to 8 weeks. Subjects will receive conjugated linoleic acid (4000 mg Tonalin FFA 80) and vitamin D3 (2000 IU) daily.
Study NCT03115775 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Corn oil (placebo)
Description: Intervention will last up to 8 weeks. Subjects will receive corn oil (4000 mg) daily.
Study NCT02201030 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP606
Description: A single intramuscular injection into the thigh
Study NCT02201030 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar13
Description: A single intramuscular injection into the thigh
Study NCT00412516 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Live attenuated SA 14-14-2 vaccine
Description: Live attenuated SA 14-14-2 vaccine coadministered with live measles vaccine (experimental Group)
Study NCT00412516 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated SA 14-14-2 vaccine
Description: Live attenuated SA 14-14-2 vaccine coadministered with live measles vaccine (experimental Group)
Study NCT04580654 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL312
Description: Fully human immunoglobulin G4/lambda recombinant monoclonal antibody against Factor XIIa
Study NCT04094012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoniazid and rifapentine
Description: This prospective multicenter randomized control trial (RCT) will be conducted on LTBI cases (see 2. Study population) to compare the risk of SDRs under conventional 3HP regimen (Arm 1: 3HP) and a new regimen consisting of daily RPT (10 mg/kg) plus INH (5 mg/kg) for 1 month (Arm 2: 1HP)
Study NCT04094012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isoniazid and rifapentine
Description: This prospective multicenter randomized control trial (RCT) will be conducted on LTBI cases (see 2. Study population) to compare the risk of SDRs under conventional 3HP regimen (Arm 1: 3HP) and a new regimen consisting of daily RPT (10 mg/kg) plus INH (5 mg/kg) for 1 month (Arm 2: 1HP)
Study NCT01866644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Bath transplanted liver with N-acetylcysteine
Study NCT01866644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Bath saline transplanted liver
Study NCT00357955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral counseling and peer support
Description: Multidisciplinary education and diabetes intervention for cardiac risk reduction - pharmacist led group intervention
Study NCT00357955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Education
Description: interactive lectures with hands-on learning